Craig Lammert

Dr. Craig Lammert

Auto-generated profile, based on publicly available information

Dr. Craig Lammert


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Hepatology
Verified
Journal Article
Closed access
CECumali Efe
Cumali Efe
AKAnand V Kulkarni
Anand V Kulkarni
BBBenedetta Terziroli Beretta‐Piccoli
Benedetta Terziroli Beretta‐Piccoli
BMBianca Magro
Bianca Magro
ASAlbert Stättermayer
Albert Stättermayer
SWStaffan Wahlin
Staffan Wahlin

1 June 2024 in Hepatology Communications
Verified
Journal Article
Open access
NRNancy S. Reau
Nancy S. Reau
CLCraig S. Lammert
Craig S. Lammert
EWEthan M. Weinberg
Ethan M. Weinberg
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease that can lead to cirrhosis and liver failure. AIH can present in all ages, races, and ethnicities, but it predominantly affects women. As a heterogeneous disease, AIH presents variably in different patients, making diagnosis and treatment a challenge. Currently, the standard treatment for AIH comprises immunosuppressants; however, their long-term use is associated with adverse effects. The pathogenesis of AIH is complex, involving T cells, macrophages, and plasma cells that invade the periportal parenchyma and lead to an inflammatory cascade that can result in liver damage. Due to the complexity of AIH pathogenesis, treatment targets several inflammatory pathways. However, unlike other autoimmune diseases in which targeted treatments have been approved, there has been little progress made in advancing the treatment paradigm for AIH. Major obstacles to progress include challenges in conducting clinical trials, particularly patient recruitment and ensuring a diverse range of backgrounds; poorly defined outcomes to assess treatment response and improved quality of life; and a lack of study designs that account for the stage of disease and variations in treatment. A focus on individualized and steroid-free treatment approaches is needed to improve AIH prognosis and minimize steroid-associated adverse effects. Export

13 March 2021 in Hepatology
Verified
Journal Article
Closed access
PDF file
CECumali Efe
Cumali Efe
RDRenumathy Dhanasekaran
Renumathy Dhanasekaran
CLCraig Lammert
Craig Lammert
BEBerat Ebik
Berat Ebik
FTFatima Higuera‐De la Tijera
Fatima Higuera‐De la Tijera
SWStaffan Wahlin
Staffan Wahlin

22 September 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
NCNaga Chalasani
Naga Chalasani
YLYi-Ju Li
Yi-Ju Li
ADAndrew Dellinger
Andrew Dellinger
VNVictor Navarro
Victor Navarro
HBHerbert Bonkovsky
Herbert Bonkovsky
JHJay H. Hoofnagle
Jay H. Hoofnagle

9 April 2021 in FEMS Microbiology Letters
Verified
Journal Article
Open access
PDF file
CLCraig Lammert
Craig Lammert
ASAndrea Shin
Andrea Shin
HXHuiping Xu
Huiping Xu
CHChristopher Hemmerich
Christopher Hemmerich
TOThomas OConnell
Thomas OConnell
NCNaga Chalasani
Naga Chalasani
The gut microbiota and metabolome could play a role in primary biliary cholangitis (PBC) progression. We aimed to assess fecal microbiota and fecal short-chain fatty acids (SCFAs) in PBC according to fibrosis. In a cross-sectional study of 23 PBC patients, fecal microbiota and SCFAs were determined using 16S rRNA sequencing and nuclear magnetic resonance spectroscopy, respectively. Fecal acetate and SCFAs were higher in advanced fibrosis. Advanced fibrosis microbiota exhibited decreased alpha diversity, increased Weisella and a distinct community composition. SCFAs correlated with individual taxa in non-advanced fibrosis. Fecal microbiota and SCFAs correspond to fibrosis in PBC.

1 September 2020 in Hepatology Communications
Verified
Journal Article
Open access
CLCraig Lammert
Craig Lammert
CZChengsong Zhu
Chengsong Zhu
YLYun Lian
Yun Lian
IRIndu Raman
Indu Raman
GEGeorge Eckert
George Eckert
NCNaga Chalasani
Naga Chalasani
Drug‐induced liver injury (DILI) sometimes presents with an autoimmune hepatitis‐like phenotype (AI‐DILI), and it is challenging to distinguish it from de novo autoimmune hepatitis (AIH). We conducted a study to identify autoantibodies unique to AI‐DILI by profiling serum autoantibodies. Autoantibodies were quantified using an autoantigen array containing 94 autoantigens from four groups: AI‐DILI (n = 65), DILI controls (n = 67), de novo AIH (n = 17), and healthy controls (HCs; n = 30). In 37 patients with AI‐DILI, samples were also collected 6 months after presentation. AI‐DILI and de novo AIH had similar anti‐neutrophil antibody and anti‐smooth muscle antibody prevalence. Compared to HCs, de novo AIH had an increase in many immunoglobulin G (IgG; 35 [46.1%]) and IgM (51 [70%]) autoantibodies, whereas AI‐DILI had an increase of IgM (40 [54.8%]) but not IgG autoantibodies. DILI controls had a similar IgG and IgM profile compared to HCs. Comparing de novo AIH to AI‐DILI identified 18 (23.7%) elevated IgG but only one (1.4%) IgM autoantibodies, indicating the unique IgG autoantibody profile in de novo AIH. Compared to DILI and HCs, increased IgM autoantibodies in AI‐DILI and de novo AIH were common; however, AI‐DILI induced by different drugs showed different frequencies of IgM autoantibodies, with nitrofurantoin‐related AI‐DILI showing a higher number of increased IgM autoantibodies. AI‐DILI autoantibody levels at diagnosis and at 6 months showed a significant decline in 37 IgM autoantibodies. A model with highly correlated IgG and IgM was fitted into multivariate logistic regression and revealed an area under the curve of 0.87 (95% confidence interval, 0.79‐0.95) to distinguish de novo AIH from AI‐DILI. Conclusion: The unique IgG and IgM autoantibody signature appears to be a promising biomarker for distinguishing AI‐DILI from de novo AIH.